https://www.selleckchem.com/pr....oducts/pirfenidone.h
Meanwhile, cyclin D1 and cyclin D2 were the direct targets of miR-892b. In addition, IL-1β-induced G1 phase arrest in chondrocytes was partially abolished by of miR-892b antagomir. In vivo study indicated miR-892b antagomir could significantly alleviate the symptom of OA in a rat model. MiR-892b antagomir inhibits the progression of OA via targeting Cyclin D1 and Cyclin D2. Thus, our finding might supply a novel target for OA treatment. MiR-892b antagomir inhibits the progression of OA via targeting Cyclin D1 and Cyclin D2. Thus, ou
Like
Comment
Share
